Get started

Financials · DARE

Dare Bioscience Inc. (DARE) financials

For the twelve months ended Jun 30, 2026, Dare Bioscience Inc. reported $1.37M of revenue and -$10.99M of net income.

Revenue, TTM
$1.37M
Net income, TTM
-$10.99M
Net margin
-804.4%
Free cash flow, TTM
-$11.76M
Cash
$12.62M
P/S
9.82
Market cap
$13.4M
Annual revenue$1.03M
FY2016FY2025
Annual net income-$13.40M
FY2016FY2025
Annual free cash flow-$10.27M
FY2016FY2025

DARE revenue and earnings growth

DARE revenueQ2 2026$187.5K

QoQ
+23.0%
FY YoY
105x

DARE revenue was $187.5K in fiscal Q2 2026 (ended Jun 30, 2026), up 23.0% from the prior quarter. For the full fiscal 2025 it was $1.03M, up about 105-fold from fiscal 2024. It rose in 1 of the last 3 fiscal years.

DARE net incomeQ2 2026-$2.98M

DARE net income was -$2.98M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$4.02M a year earlier. For the full fiscal 2025 it was -$13.40M, compared with -$4.05M in fiscal 2024.

DARE EPSQ2 2026-$0.20

DARE diluted EPS was -$0.20 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$1.20, compared with -$0.48 in fiscal 2024.

DARE free cash flowQ2 2026-$6.86M

DARE free cash flow was -$6.86M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$5.57M a year earlier. For the full fiscal 2025 it was -$10.27M, compared with $4.90M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$1.03M$9.8K$2.81M$10.00M$0----$766.0K
Cost of revenue$295.8K$0--------
Gross profit$734.4K$9.8K--------
Research and development$5.52M$14.31M$21.54M$30.04M$30.62M$20.77M$8.55M$6.41M$984.7K$72.7K
Selling, general and admin$8.76M$9.16M$12.11M$11.24M$8.35M$6.55M$5.27M$4.66M$2.70M$157.9K
Operating income-$13.55M-$23.45M-$30.94M-$31.39M-$39.07M-$27.40M-$14.34M-$16.88M-$11.18M-$630.6K
Interest expense--------$322.6K$42.1K
Pre-tax income-$13.54M-$4.05M-$30.16M-$30.95M-$38.70M-$27.40M-$14.26M-$16.81M-$11.52M-$673.0K
Income tax$0$0$0$0$0$0$0$3.2K$0-
Net income-$13.40M-$4.05M-$30.16M-$30.95M-$38.70M-$27.40M-$14.26M-$16.74M-$11.50M-$672.7K
EPS, basic-$1.20-$0.48-$4.15-$4.44-$7.56-$10.92-$11.64-$18.84$42.72-$9.72
EPS, diluted-$1.20-$0.48-$4.15-$4.44-$7.56-$10.92-$11.64-$18.84$42.72-$9.72
Diluted shares11.2M8.5M7.3M7.0M5.1M2.5M1.3M894,368.417269,356.569,583.333

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$24.71M$16.00M$10.81M$34.67M$51.67M$4.67M$4.78M$6.81M$7.56M$44.6K
Receivables----$0----$823.0K
Current assets$27.06M$18.45M$17.54M$43.04M$55.30M$6.98M$6.44M$7.24M$8.35M$44.6K
Goodwill-------$0$5.20M-
Total assets$32.47M$22.10M$21.28M$43.83M$55.81M$7.55M$7.44M$7.83M$14.26M$44.6K
Current liabilities$23.69M$21.61M$20.48M$31.62M$16.05M$7.66M$5.61M$1.09M$966.7K$755.2K
Short-term debt-$4.1K--------
Total liabilities$29.63M$28.11M$26.33M$32.71M$17.05M$8.70M$7.00M$1.10M$967.0K$755.2K
Shareholders' equity$2.84M-$6.01M-$5.05M$11.11M$38.75M-$1.15M$440.8K$6.73M$13.29M-$710.6K

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$9.89M$5.47M-$38.86M-$18.09M-$28.76M-$25.23M-$13.32M-$10.27M-$2.54M-$372.3K
Capital expenditures$385.3K$573.0K$629.4K$63.1K$14.5K$17.6K$0$11.8K$0$535.0K
Free cash flow-$10.27M$4.90M-$39.49M-$18.15M-$28.78M-$25.25M-$13.32M-$10.28M-$2.54M-$907.3K
Investing cash flow-$385.3K-$573.0K-$629.4K-$63.1K-$14.5K-$17.6K$6.14M-$518.8K$9.92M-$418.0K
Financing cash flow$19.28M$354.5K$15.64M$1.34M$75.85M$25.13M$5.15M$10.11M$155.0K$197.5K
Stock-based compensation$1.50M$2.20M$2.53M$2.16M$1.60M$742.0K$462.2K$139.3K$15.8K$9.0K
Depreciation and amortization$1.63M$42.3K-------$261.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY10429.4%-99.7%-71.9%-------
Gross margin71.3%100.0%--------
Operating margin-1315.5%-239692.2%-1101.9%-313.9%------82.3%
Net margin-1300.7%-41430.9%-1074.2%-309.5%------87.8%
Free cash flow margin-997.0%50087.0%-1406.3%-181.5%------118.4%
Return on equity-471.4%---278.5%-99.8%--3235.7%-248.8%-86.5%-
Return on assets-41.3%-18.3%-141.7%-70.6%-69.3%-362.9%-191.6%-213.8%-80.7%-1507.8%
Current ratio1.140.850.861.363.440.911.156.648.640.06

Source: XBRL data Dare Bioscience Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Aug 14, 2017; 1-for-12, first reported Aug 12, 2024.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

DARE peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
DARE$1.37M--$10.99M-804.4%$13.4M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

DARE FAQ

7 questions
  • What is DARE revenue?
    Dare Bioscience Inc. (DARE) reported $1.37M of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2025 was $1.03M.
  • Is DARE profitable?
    No. Dare Bioscience Inc. reported a net loss of $10.99M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does DARE have?
    Dare Bioscience Inc. reported $12.62M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is DARE revenue growing?
    Dare Bioscience Inc.'s revenue changed 105x in fiscal 2025, to $1.03M.
  • What is DARE free cash flow?
    Dare Bioscience Inc. generated -$11.76M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$11.29M less capital expenditures.
  • When did DARE last report financial results?
    The latest statements here come from Dare Bioscience Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.
  • Where does this DARE financial data come from?
    Quantisnow builds these statements from the structured XBRL data Dare Bioscience Inc. files with the SEC. It is provided for information only and is not investment advice.